Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

730
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
730
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

612
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
612
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
Pneumothorax-II01:27

Pneumothorax-II

1.3K
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain white matter microstructural integrity differences between pre-post buprenorphine-naloxone treated individuals with opioid use disorder: Evidence from a DTI study.

Psychiatry research. Neuroimaging·2026
Same author

Invasive mould infections of the central nervous system in the Indian population: a cohort study (2004-2025).

The Lancet regional health. Southeast Asia·2026
Same author

Role of Advanced Multimodality Synthetic MRI and Dynamic Contrast-Enhanced MRI Derived Parameters in the Differentiating Neurocysticercosis and Tuberculomas.

Clinical neuroradiology·2026
Same author

Patterns and Factors Associated With Cerebral Infarction on MRI in Tuberculous Meningitis: Secondary Analysis of the ACT-TBM Trial.

Stroke·2026
Same author

Buprenorphine and Surface-based Brain Morphometry: Impacts on Cortical Thickness, Depth, and Gyrification in Patients with Opioid Use Disorder.

Indian journal of psychological medicine·2025
Same author

Diagnosing tuberculous meningitis from cell-free DNA by multi-targeted real-time PCR: An experience from 170 cases.

Tuberculosis (Edinburgh, Scotland)·2025

Related Experiment Video

Updated: Mar 15, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

736

Six months therapy for tuberculous meningitis.

Sophie Jullien1, Hannah Ryan, Manish Modi

  • 1Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK.

The Cochrane Database of Systematic Reviews
|September 2, 2016
PubMed
Summary

Short-course antituberculous treatment (ATT) for tuberculous meningitis (TBM) showed similar relapse rates but higher clinical cure rates compared to longer regimens. Further research is needed to confirm findings in HIV-positive individuals.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Related Experiment Videos

Last Updated: Mar 15, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

736
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.3K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.4K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Public Health

Background:

  • Tuberculous meningitis (TBM) is a severe central nervous system infection with high mortality and disability rates.
  • Current guidelines recommend longer antituberculous treatment (ATT) for TBM than pulmonary tuberculosis to prevent relapse.
  • Longer ATT regimens may lead to poor adherence, drug resistance, and increased costs.

Purpose of the Study:

  • To compare the effectiveness and safety of six-month versus prolonged-course ATT regimens for TBM.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) and prospective cohort studies.
  • Searched multiple databases up to March 2016, including Cochrane, MEDLINE, EMBASE, and clinical trial registries.
  • Included studies with a minimum of six months follow-up post-treatment; primary outcome was relapse.

Main Results:

  • 1881 participants from 4 RCTs and 12 cohort studies were included; no direct comparison RCTs were found.
  • Relapse rates were low and similar between six-month (0.8%) and longer-course (0.8%) regimens.
  • Higher clinical cure rates were observed with six-month regimens (89.1%) compared to longer regimens (73.7%); higher mortality was seen in longer-course groups, likely due to confounding.

Conclusions:

  • Relapse is uncommon in TBM regardless of ATT duration; most deaths occur early in treatment.
  • Current data are primarily from HIV-negative individuals, limiting generalizability to HIV-positive populations.
  • Well-designed RCTs or large prospective cohort studies with long follow-up are needed to definitively assess six-month TBM treatment efficacy and safety.